頁籤選單縮合
題 名 | 雙磷酸鹽類與心律不整之風險=Bisphosphonates and Risk of Atrial Fibrillation |
---|---|
作 者 | 陳崇鈺; 黃耀斌; | 書刊名 | 藥學雜誌 |
卷 期 | 30:2=119 2014.06[民103.06] |
頁 次 | 頁148-152 |
分類號 | 418.2183 |
關鍵詞 | 雙磷酸鹽類; 心律不整; 安全性評估; Bisphosphonate; Atrial fibrillation; Safety assessment; |
語 文 | 中文(Chinese) |
中文摘要 | 2007年藥物不良反應通報中心,雖曾發布 bisphosphonate 類藥品與心律不整之安 全性報告,但到目前為止,仍未有足夠的資料及文獻對其安全性作出評估。根據2013 年之整合分析發現,由觀察性研究與臨床試驗結果可知道,使用雙磷酸鹽類藥品相對 於未使用者而言,前者顯著增加心律不整之風險,但卻未增加中風及心血管死亡率。 根據目前藥品上市後研究及藥理研究,仍無法清楚地了解,使用雙磷酸鹽類藥品對於 心房顫動及其他心血管疾病之風險。因此,對於雙磷酸鹽類藥品之安全性評估,仍須 要有更長時間、不同領域來進行分析與探討。 |
英文摘要 | According to Taiwan National Adverse Drug Reactions Reporting System had reported an association between bisphosphonate use and the onset of atrial fibrillation。However, there are still limited information about the risk assessment of bisphosphonate use and the onset of atrial fibrillation. Based on a meta-analysis on 2013 year, the pooling outcomes of observational studies and clinical trials indicated an increased risk of atrial fibrillation among bisphosphonate users, but not observed in stroke or cardiovascular mortality. Moreover, current evidence is not still clearly understood the correlation and mechanism of bisphosphonate use and the onset of atrial fibrillation. Therefore, longer-time database and more field researches need to be conducted to assess the risk and benefit of bisphosphonate and atrial fibrillation. |
本系統中英文摘要資訊取自各篇刊載內容。